Lung Cancer | Specialty

Checkpoint Inhibition for Mesothelioma, Thymic Malignancies

February 27th 2015

Necitumumab in Squamous NSCLC

February 27th 2015

Ramucirumab in Metastatic NSCLC

February 27th 2015

Maintenance Combination Therapy in NSCLC

February 27th 2015

Chemotherapy Regimens in Metastatic NSCLC

February 27th 2015

Treating Driver Mutation Negative NSCLC

February 27th 2015

Novel ALK Inhibitors in NSCLC With Brain Metastases

February 27th 2015

Treatments for ALK-Positive NSCLC

February 27th 2015

ALK Inhibition in NSCLC

February 27th 2015

Types of EGFR Therapy in NSCLC

February 27th 2015

Overcoming EGFR Inhibitor Resistance in NSCLC

February 27th 2015

Bevacizumab in Non-Small Cell Lung Cancer

February 27th 2015

First-Line Therapy in EGFR-Mutant Lung Cancer

February 27th 2015

Molecular Testing in Non-Small Cell Lung Cancer

February 27th 2015

Phase III Motesanib Trial in NSCLC Misses Primary Endpoint

February 17th 2015

The oral multikinase inhibitor motesanib failed to meet the primary endpoint of improving progression-free survival in patients with non–small cell lung cancer in the phase III MONET-A trial.

Dr. Brahmer on Immunotherapy Development in Lung Cancer

February 17th 2015

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses immunotherapy and how it can advance as a treatment option for patients with lung cancer.

Medicare Will Cover LDCT Screening for High-Risk Individuals

February 6th 2015

Medicare will immediately cover lung cancer screening with low-dose computed tomography for high-risk individuals, including current and former smokers.

FDA Grants Breakthrough Status to PD-L1 Inhibitor MPDL3280A in NSCLC

February 2nd 2015

The anti–PD-L1 agent MPDL3280A has received a breakthrough therapy designation from the FDA for PD-L1–positive non–small cell lung cancer that has progressed during or after platinum-based chemotherapy, as well as a targeted therapy for patients with EGFR- or ALK-positive tumors.

Dr. Belani on PD-1 Inhibitors for Non-Small Cell Lung Cancer

January 28th 2015

Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses the benefits of immunotherapy for lung cancer.

Brahmer Expects Rapid Approval for First PD-1 Inhibitor in Lung Cancer

January 25th 2015

Immune checkpoint inhibitors targeted against PD-1 and its ligand PD-L1 have rapidly advanced as treatments for patients with melanoma and non–small cell lung cancer (NSCLC), following their initial debut in 2012.